Published in Proc Natl Acad Sci U S A on February 15, 2000
Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A (2005) 4.63
Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol (2008) 2.84
The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia (2006) 2.30
Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci U S A (2002) 1.93
Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res (2009) 1.89
MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells. Oncogene (2011) 1.86
Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging (2010) 1.82
Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med (2004) 1.73
Chemotherapeutic approaches for targeting cell death pathways. Oncologist (2006) 1.70
Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci U S A (2005) 1.69
TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia (2002) 1.61
Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5. Int J Radiat Oncol Biol Phys (2008) 1.56
TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol (2009) 1.51
A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia (2007) 1.50
Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod Biol Endocrinol (2003) 1.48
Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci U S A (2006) 1.45
TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat (2008) 1.44
Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer. Breast Cancer Res (2009) 1.42
TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets (2007) 1.36
Induction of cell death in human immunodeficiency virus-infected macrophages and resting memory CD4 T cells by TRAIL/Apo2l. J Virol (2001) 1.34
Pretreatment prediction of brain tumors' response to radiation therapy using high b-value diffusion-weighted MRI. Neoplasia (2004) 1.32
Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts. Korean J Radiol (2012) 1.24
Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody. Radiology (2008) 1.20
Erythroid differentiation sensitizes K562 leukemia cells to TRAIL-induced apoptosis by downregulation of c-FLIP. Mol Cell Biol (2003) 1.17
Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. Cancer Res (2008) 1.17
TRAIL gene therapy: from preclinical development to clinical application. Curr Gene Ther (2009) 1.13
A new dawn for the use of traditional Chinese medicine in cancer therapy. Mol Cancer (2009) 1.10
ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2. Apoptosis (2012) 1.09
Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck. Transl Oncol (2008) 1.09
Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer (2005) 1.08
The TRAIL to targeted therapy of breast cancer. Adv Cancer Res (2009) 1.08
Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL. J Biol Chem (2003) 1.04
Combined modality therapy with TRAIL or agonistic death receptor antibodies. Cancer Biol Ther (2011) 1.02
Regulation of ERalpha-mediated transcription of Bcl-2 by PI3K-AKT crosstalk: implications for breast cancer cell survival. Int J Oncol (2010) 1.01
Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival. Apoptosis (2008) 0.99
TPL2 kinase is a suppressor of lung carcinogenesis. Proc Natl Acad Sci U S A (2013) 0.99
Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus. Clin Cancer Res (2006) 0.97
Current concepts in clinical radiation oncology. Radiat Environ Biophys (2013) 0.97
2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2. Mol Cancer (2009) 0.97
Caspase-mediated cleavage of beta-catenin precedes drug-induced apoptosis in resistant cancer cells. J Biol Chem (2009) 0.96
Death receptor pathways mediate targeted and non-targeted effects of ionizing radiations in breast cancer cells. Carcinogenesis (2009) 0.94
Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression. BMC Cancer (2007) 0.94
Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells. Cancer Res (2009) 0.94
Apoptosis induction in renal cell carcinoma by TRAIL and gamma-radiation is impaired by deficient caspase-9 cleavage. Br J Cancer (2003) 0.92
Bisphenol A diglycidyl ether induces apoptosis in tumour cells independently of peroxisome proliferator-activated receptor-gamma, in caspase-dependent and -independent manners. Biochem J (2002) 0.92
ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. Breast Cancer Res Treat (2011) 0.91
Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines. Br J Cancer (2003) 0.91
Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector. Neoplasia (2002) 0.91
WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis. Mol Cancer Res (2011) 0.91
RRR-gamma-tocopherol induces human breast cancer cells to undergo apoptosis via death receptor 5 (DR5)-mediated apoptotic signaling. Cancer Lett (2007) 0.91
Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography imaging biomarkers. Clin Cancer Res (2010) 0.90
Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer. Clin Cancer Res (2005) 0.89
Imaging proteolytic activity in live cells and animal models. PLoS One (2013) 0.89
Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening. Breast Cancer Res (2014) 0.88
Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model. J Cell Biochem (2009) 0.88
Lovastatin sensitized human glioblastoma cells to TRAIL-induced apoptosis. J Neurooncol (2007) 0.88
Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5. BMC Cancer (2011) 0.87
Clinical significance of magnetic resonance imaging findings in rectal cancer. World J Radiol (2011) 0.86
MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells. PLoS One (2013) 0.86
Targeting apoptosis signaling pathways for anticancer therapy. Front Oncol (2011) 0.85
TNF superfamily gene polymorphism as prognostic factor in early breast cancer. J Cancer Res Clin Oncol (2009) 0.84
Radiation-induced tumor neoantigens: imaging and therapeutic implications. Am J Cancer Res (2011) 0.84
Characterization of the Interactions between Calmodulin and Death Receptor 5 in Triple-negative and Estrogen Receptor-positive Breast Cancer Cells: AN INTEGRATED EXPERIMENTAL AND COMPUTATIONAL STUDY. J Biol Chem (2016) 0.84
The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma. J Cancer Res Clin Oncol (2010) 0.83
Diffusion MRI in early cancer therapeutic response assessment. NMR Biomed (2016) 0.83
Multi-site clinical evaluation of DW-MRI as a treatment response metric for breast cancer patients undergoing neoadjuvant chemotherapy. PLoS One (2015) 0.83
Early therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and (1)H MR spectroscopy. J Magn Reson Imaging (2013) 0.82
Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys (2006) 0.82
Antitumor activity of TRAIL recombinant adenovirus in human malignant glioma cells. J Korean Med Sci (2005) 0.81
Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer. Cancers (Basel) (2011) 0.80
TRAIL-induced apoptosis is enhanced by heat shock protein 70 expression. Cell Stress Chaperones (2006) 0.80
Depletion of CABYR-a/b sensitizes lung cancer cells to TRAIL-induced apoptosis through YAP/p73-mediated DR5 upregulation. Oncotarget (2016) 0.79
Tumor progression locus 2 (Tpl2) kinase as a novel therapeutic target for cancer: double-sided effects of Tpl2 on cancer. Int J Mol Sci (2015) 0.79
The antidiabetic drug ciglitazone induces high grade bladder cancer cells apoptosis through the up-regulation of TRAIL. PLoS One (2011) 0.78
A transgenic mouse for imaging caspase-dependent apoptosis within the skin. J Invest Dermatol (2010) 0.77
The bioinformatics analysis of miRNAs signatures differentially expressed in HER2(+) versus HER2(-) breast cancers. Cancer Biother Radiopharm (2012) 0.77
TNF related apoptosis-inducing ligand and its receptors in ocular tumors. Int J Ophthalmol (2011) 0.76
Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer. Cancer Biol Ther (2013) 0.76
Early changes in apparent diffusion coefficient as an indicator of response to sorafenib in hepatocellular carcinoma. J Zhejiang Univ Sci B (2014) 0.76
Effects of Normothermic Conditioned Microwave Irradiation on Cultured Cells Using an Irradiation System with Semiconductor Oscillator and Thermo-regulatory Applicator. Sci Rep (2017) 0.75
The combination of TRAIL treatment and cancer cell selective expression of TRAIL-death receptor DR4 induces cell death in TRAIL-resistant cancer cells. Yonsei Med J (2006) 0.75
Regulation of cell death in cancer-possible implications for immunotherapy. Front Oncol (2013) 0.75
Predicting treatment efficacy via quantitative magnetic resonance imaging: a Bayesian joint model. J R Stat Soc Ser C Appl Stat (2011) 0.75
Rays Sting: The Acute Cellular Effects of Ionizing Radiation Exposure. Transl Med UniSa (2016) 0.75
Feedback Regulation in a Cancer Stem Cell Model can Cause an Allee Effect. Bull Math Biol (2016) 0.75
Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology. Oncol Rev (2017) 0.75
Targeting Melanoma with Cancer-Killing Viruses. Open Virol J (2017) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Death receptors: signaling and modulation. Science (1998) 16.95
Apoptosis by death factor. Cell (1997) 14.42
FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex. Cell (1996) 12.07
Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell (1996) 9.93
FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell (1995) 9.81
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med (1999) 9.78
Lethal effect of the anti-Fas antibody in mice. Nature (1993) 9.20
Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 7.69
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (1997) 6.82
The receptor for the cytotoxic ligand TRAIL. Science (1997) 6.39
An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science (1997) 6.10
A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem (1995) 5.34
Two TNF receptors. Immunol Today (1992) 4.87
Apoptosis control by death and decoy receptors. Curr Opin Cell Biol (1999) 4.54
Treatment of breast cancer. N Engl J Med (1998) 4.32
An induced proximity model for caspase-8 activation. J Biol Chem (1998) 4.18
FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem (1996) 3.72
Removal of endotoxin from protein solutions by phase separation using Triton X-114. J Immunol Methods (1990) 3.48
Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol Cell Biol (1992) 3.37
Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol (1998) 2.49
Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res (1994) 2.31
A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol (1997) 2.31
Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature (1998) 2.29
Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia (1999) 2.24
p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res (1998) 2.02
Removal of endotoxin from recombinant protein preparations. Clin Biochem (1997) 1.95
The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J Exp Med (1988) 1.77
Fas and Fas ligand: a death factor and its receptor. Adv Immunol (1994) 1.63
Ultraviolet radiation-induced apoptosis is mediated by activation of CD-95 (Fas/APO-1). J Biol Chem (1997) 1.56
TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett (1998) 1.54
Amplification of c-erbB-2 and aggressive human breast tumors? Science (1988) 1.43
Fas-mediated apoptosis in primary cultured mouse hepatocytes. Exp Cell Res (1994) 1.41
Early growth response-1-dependent apoptosis is mediated by p53. J Biol Chem (1997) 1.40
Optimized isotropic diffusion weighting. Magn Reson Med (1995) 1.21
Sublethal damage, potentially lethal damage, and chromosomal aberrations in mammalian cells exposed to ionizing radiations. Int J Radiat Oncol Biol Phys (1991) 1.12
Portrait of an executioner: the molecular mechanism of FAS/APO-1-induced apoptosis. Semin Immunol (1997) 1.11
The radiobiology of human cells and tissues. In vitro radiosensitivity. The picture has changed in the 1980s. Int J Radiat Biol (1989) 1.05
Mutant p53-induced immortalization of primary human mammary epithelial cells. Cancer Res (1996) 1.02
Mutant p53 proteins behave in a dominant, negative fashion in vivo. Anticancer Res (1995) 0.92
Mining the genome for drugs. Science (1999) 0.82
Gluconeogenesis in the perfused rat liver. Biochem J (1966) 8.58
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst (2000) 5.14
Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med (1995) 4.62
Diagnosis of pulmonary embolism with magnetic resonance angiography. N Engl J Med (1997) 3.48
Examination of a case of suspected McArdle's syndrome by 31P nuclear magnetic resonance. N Engl J Med (1981) 3.00
Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia (2001) 2.97
Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res (1997) 2.96
Thrombin-soaked gelatin sponge and brain edema in rats. J Neurosurg (1996) 2.65
Development of the human brain: in vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy. Magn Reson Med (1993) 2.59
Can consultants resuscitate? J R Coll Physicians Lond (1992) 2.43
Metabolic activities of the isolated perfused rat kidney. Biochem J (1967) 2.41
Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology (1995) 2.20
The stabilized ring retractor: a technique for cholecystectomy. Br J Surg (1987) 2.19
Ultra-fast three dimensional imaging of hyperpolarized 13C in vivo. MAGMA (2005) 2.17
Carbohydrate metabolism of the perfused rat liver. Biochem J (1967) 2.08
Metabolic disorders of the brain in chronic hepatic encephalopathy detected with H-1 MR spectroscopy. Radiology (1992) 2.07
Cloning of rfaG, B, I, and J genes for glycosyltransferase enzymes for synthesis of the lipopolysaccharide core of Salmonella typhimurium. J Bacteriol (1985) 2.04
Expression of the Epstein-Barr virus BamHI A fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo. J Virol (1991) 1.91
Contributions of cell kill and posttreatment tumor growth rates to the repopulation of intracerebral 9L tumors after chemotherapy: an MRI study. Proc Natl Acad Sci U S A (1998) 1.91
3-D FLASH imaging using a single surface coil and a new adiabatic pulse, BIR-4. Invest Radiol (1990) 1.88
Sodium reabsorption in the perfused rat kidney. Am J Physiol (1973) 1.82
Brief report: organic osmolytes in the brain of an infant with hypernatremia. N Engl J Med (1994) 1.81
Experimental intracerebral hemorrhage: relationship between brain edema, blood flow, and blood-brain barrier permeability in rats. J Neurosurg (1994) 1.78
The role of apoptosis in 2',2'-difluoro-2'-deoxycytidine (gemcitabine)-mediated radiosensitization. Clin Cancer Res (2001) 1.74
Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia (2000) 1.72
Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem (1991) 1.67
Decreased motor cortex γ-aminobutyric acid in amyotrophic lateral sclerosis. Neurology (2012) 1.64
The effects of time varying intravascular signal intensity and k-space acquisition order on three-dimensional MR angiography image quality. J Magn Reson Imaging (1996) 1.61
Enzyme distribution along the nephron. Kidney Int (1984) 1.60
Sigma factor-anti-sigma factor interaction in alginate synthesis: inhibition of AlgT by MucA. J Bacteriol (1996) 1.59
Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol (1995) 1.58
Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology (1993) 1.58
Tricarboxylic acid cycle of glia in the in vivo human brain. NMR Biomed (2002) 1.57
Alginate, inorganic polyphosphate, GTP and ppGpp synthesis co-regulated in Pseudomonas aeruginosa: implications for stationary phase survival and synthesis of RNA/DNA precursors. Mol Microbiol (1998) 1.50
Thyroid metastasis from nasopharyngeal carcinoma: a case report. J Laryngol Otol (1994) 1.48
Cerebral metabolic disturbances in patients with subacute and chronic diabetes mellitus: detection with proton MR spectroscopy. Radiology (1992) 1.47
Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res (1999) 1.45
Accumulation of methylsulfonylmethane in the human brain: identification by multinuclear magnetic resonance spectroscopy. Toxicol Lett (2001) 1.44
In vivo MR determination of water diffusion coefficients and diffusion anisotropy: correlation with structural alteration in gliomas of the cerebral hemispheres. AJNR Am J Neuroradiol (1995) 1.44
Induction of cytotoxic oxidative stress by D-alanine in brain tumor cells expressing Rhodotorula gracilis D-amino acid oxidase: a cancer gene therapy strategy. Hum Gene Ther (1998) 1.43
Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy. Gene Ther (2000) 1.42
Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res (1997) 1.42
Order information in working memory: fMRI evidence for parietal and prefrontal mechanisms. J Cogn Neurosci (2000) 1.41
Breath-hold gadolinium-enhanced MR angiography of the abdominal aorta and its major branches. Radiology (1995) 1.41
Mediastinal lymph nodes: relaxation time/pathologic correlation and implications in staging of lung cancer with MR imaging. Radiology (1988) 1.41
Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. Eur Radiol (2012) 1.38
31P NMR examination of two patients with NADH-CoQ reductase deficiency. Nature (1982) 1.37
Signal-to-noise measures for magnetic resonance imagers. Magn Reson Imaging (1993) 1.35
Diffusion imaging for evaluation of tumor therapies in preclinical animal models. MAGMA (2004) 1.33
The bZIP transcription factor Nrl stimulates rhodopsin promoter activity in primary retinal cell cultures. J Biol Chem (1996) 1.30
PACE/furin can process the vitamin K-dependent pro-factor IX precursor within the secretory pathway. J Biol Chem (1993) 1.30
Antibody mapping of tissue factor implicates two different exon-encoded regions in function. Biochem J (1991) 1.30
Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas. Am J Pathol (1992) 1.28
Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy. Proc Natl Acad Sci U S A (1999) 1.26
Biochemical characterization and subcellular localization of the mouse retinitis pigmentosa GTPase regulator (mRpgr). J Biol Chem (1998) 1.24
Quantum back-action of an individual variable-strength measurement. Science (2013) 1.24
Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast Cancer Res (2000) 1.23
Improved function with amino acids in the isolated perfused kidney. Am J Physiol (1982) 1.23
Nucleoside diphosphate kinase from Pseudomonas aeruginosa: characterization of the gene and its role in cellular growth and exopolysaccharide alginate synthesis. Mol Microbiol (1996) 1.20
Terahertz pulsed imaging of basal cell carcinoma ex vivo and in vivo. Br J Dermatol (2004) 1.20
Motion correction in fMRI via registration of individual slices into an anatomical volume. Magn Reson Med (1999) 1.19
Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo. Gene Ther (1998) 1.19
Proprotein convertase expression and localization in epidermis: evidence for multiple roles and substrates. Exp Dermatol (2001) 1.17
Pheochromocytoma and paraganglioma: comparison of MR imaging with CT and I-131 MIBG scintigraphy. Radiology (1987) 1.17
Cloning and functional expression of a cDNA encoding the catalytic subunit of bovine enterokinase. J Biol Chem (1993) 1.16
Cloning and analysis of the sfrB (sex factor repression) gene of Escherichia coli K-12. J Bacteriol (1986) 1.15
Carboxy-terminal conversion of profibrillin to fibrillin at a basic site by PACE/furin-like activity required for incorporation in the matrix. J Cell Sci (1999) 1.15
Assessment of the role of the glutathione and pentose phosphate pathways in the protection of primary cerebrocortical cultures from oxidative stress. J Neurochem (1996) 1.14
Salivary and serum IgA antibodies to the Epstein-Barr virus glycoprotein gp340: incidence and potential for virus neutralization. Int J Cancer (1991) 1.14
Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med (1994) 1.13
A role for PACE4 in the proteolytic activation of anthrax toxin protective antigen. Infect Immun (1997) 1.13
Cofactor residues lysine 165 and 166 are critical for protein substrate recognition by the tissue factor-factor VIIa protease complex. J Biol Chem (1992) 1.13
Metabolic imaging of mild traumatic brain injury. Brain Imaging Behav (2012) 1.12
The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model. Gene Ther (2002) 1.12
Energy metabolism and alginate biosynthesis in Pseudomonas aeruginosa: role of the tricarboxylic acid cycle. J Bacteriol (1994) 1.11
Automated detection of bolus arrival and initiation of data acquisition in fast, three-dimensional, gadolinium-enhanced MR angiography. Radiology (1997) 1.11
Three-dimensional static displacement, stimulated echo NMR elasticity imaging. Phys Med Biol (2000) 1.09
MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agent. J Magn Reson Imaging (1997) 1.08
In vivo magnetic resonance imaging of hyperpolarized silicon particles. Nat Nanotechnol (2013) 1.08
Growth kinetics and treatment response of the intracerebral rat 9L brain tumor model: a quantitative in vivo study using magnetic resonance imaging. Clin Cancer Res (1995) 1.07
Early castration reduces prostatic carcinogenesis in transgenic mice. Urology (1999) 1.07
Effect of inhibition of gluconeogenesis on ammonia production in the perfused rat kidney. Clin Sci Mol Med (1976) 1.07
Elevated serum levels of transforming growth factor beta1 in Epstein-Barr virus-associated nasopharyngeal carcinoma patients. Int J Cancer (1999) 1.07
Gallstone perforation of the ileum without obstruction. Postgrad Med J (1984) 1.06
Membrane type matrix metalloproteinase 1 activates pro-gelatinase A without furin cleavage of the N-terminal domain. J Biol Chem (1996) 1.06
Direct determination of the N-acetyl-L-aspartate synthesis rate in the human brain by (13)C MRS and [1-(13)C]glucose infusion. J Neurochem (2001) 1.05
Clinical magnetic susceptibility mapping of the brain. J Comput Assist Tomogr (1987) 1.04
The effect of experimental bile-duct obstruction on critical biosynthetic functions of the liver. Br J Surg (1972) 1.04
Subclavian MR arteriography: reduction of susceptibility artifact with short echo time and dilute gadopentetate dimeglumine. Radiology (2000) 1.04
Epstein-Barr virus nuclear antigen 1 linear epitopes that are reactive with immunoglobulin A (IgA) or IgG in sera from nasopharyngeal carcinoma patients or from healthy donors. J Clin Microbiol (1991) 1.03